Ultralife

ULBI

Market cap $94.7M

Ultralife Corporation ( ULBI ) Q3 2025 Earnings Call November 18, 2025 8:30 AM EST Company Participants Michael Manna - President, CEO & Director Philip A. Fain - CFO, Treasurer & Corporate Secretary Conference Call Participants Jody Burfening - Lippert/Heilshorn & Associates, Inc. Presentation Operator Good day, and thank you for standing by.

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results:

NEWARK, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its third quarter results for the period ended September 30, 2025 before the market opens on Tuesday, November 18, 2025.

NEWARK, N.Y., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Form 10-Q for the third quarter ended September 30, 2025.

NEWARK, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) has received an award valued at approximately $5.2 million from the U.S. Government's Defense Logistics Agency (“DLA”) for its lithium manganese dioxide, non-rechargeable BA-5390 military batteries. The majority of the shipments are scheduled throughout 2026 with completion in early 2027.

Ultralife Corporation (NASDAQ:ULBI ) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Michael E. Manna - President, CEO & Director Philip A.

Ultralife (ULBI -17.03%), a specialty battery and communications systems manufacturer, reported its second quarter 2025 earnings on August 7, 2025, covering the period ended June 30. The report showed headline revenue (GAAP) grew 13.0% to $48.6 million, driven by the Electrochem acquisition.

NEWARK, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its second quarter results for the period ended June 30, 2025 before the market opens on Thursday, August 7, 2025.

Ultralife was removed from the FTSE Russell 3000 Microcap Index due to a share price slump, but fundamentals remain strong, and recovery is underway. Recent earnings show robust revenue and EPS growth, boosted by the Electrochem acquisition and improved productivity, supporting a bullish outlook. The valuation remains attractive, with forecasted EPS growth and a one-year price target of $14.12, representing a significant upside from current levels.

Ultralife's revenue has been volatile in the past decade or so, but its recent comeback seems to have more legroom to grow. Through a series of recent acquisitions, the company has diversified its revenue dependence on government contracts and obtained access to a more domestic and overseas customer base. Key financial metrics demonstrate strong cash flow and organic integration of its acquisitions, supporting a positive outlook.